Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/69873
Título: | COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions? |
Autor(es): | Arastehfar, Amir Carvalho, Agostinho Nguyen, M. Hong Hedayati, Mohammad Taghi Netea, Mihai G. Perlin, David S. Hoenigl, Martin |
Palavras-chave: | candidemia candiduria oral candidiasis mycobiome COVID-19 |
Data: | 2020 |
Editora: | Multidisciplinary Digital Publishing Institute |
Revista: | Journal of Fungi |
Citação: | Arastehfar, A.; Carvalho, A.; Nguyen, M.H.; Hedayati, M.T.; Netea, M.G.; Perlin, D.S.; Hoenigl, M. COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions? J. Fungi 2020, 6, 211. https://doi.org/10.3390/jof6040211 |
Resumo(s): | The recent global pandemic of COVID-19 has predisposed a relatively high number of patients to acute respiratory distress syndrome (ARDS), which carries a risk of developing super-infections. <i>Candida</i> species are major constituents of the human mycobiome and the main cause of invasive fungal infections, with a high mortality rate. Invasive yeast infections (IYIs) are increasingly recognized as s complication of severe COVID-19. Despite the marked immune dysregulation in COVID-19, no prominent defects have been reported in immune cells that are critically required for immunity to <i>Candida</i>. This suggests that relevant clinical factors, including prolonged ICU stays, central venous catheters, and broad-spectrum antibiotic use, may be key factors causing COVID-19 patients to develop IYIs. Although data on the comparative performance of diagnostic tools are often lacking in COVID-19 patients, a combination of serological and molecular techniques may present a promising option for the identification of IYIs. Clinical awareness and screening are needed, as IYIs are difficult to diagnose, particularly in the setting of severe COVID-19. Echinocandins and azoles are the primary antifungal used to treat IYIs, yet the therapeutic failures exerted by multidrug-resistant <i>Candida</i> spp. such as <i>C. auris</i> and <i>C. glabrata</i> call for the development of new antifungal drugs with novel mechanisms of action. |
Tipo: | Artigo |
URI: | https://hdl.handle.net/1822/69873 |
DOI: | 10.3390/jof6040211 |
e-ISSN: | 2309-608X |
Versão da editora: | https://www.mdpi.com/2309-608X/6/4/211 |
Arbitragem científica: | yes |
Acesso: | Acesso aberto |
Aparece nas coleções: | ICVS - Artigos em revistas internacionais / Papers in international journals |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
jof-06-00211.pdf | 263,2 kB | Adobe PDF | Ver/Abrir |
Este trabalho está licenciado sob uma Licença Creative Commons